Lawton J,Ahmad N,Hallowell N,et al.Perceptions and experiences of taking oral hypoglycaemic agents among people of Pakistani and Indian origin:qualitative study[J].BMJ,2005,330:1247.
[2]
Ahmedani MY,Haque MS,Basit A,et al.Ramadan Prospective Diabetes Study:the role of drug dosage and timing alteration,active glucose monitoring and patient education[J].Diabet Med,2012,29:709-715.
[3]
Monami M,Iacomelli I,Marchionni N,et al.Dipeptydil peptidase-4 inhibitors in type 2 diabetes:a meta-analysis of randomized clinical trials[J].Nutr Metab Cardiovasc Dis,2010,20:224-235.
[4]
BolliG,Dotta F,Roehotte E,et al.Efficacy and to letability of vildagliptin vs.pilglitazon when added to metform in a 24-week Falldomized,double-blind study [J].Diabetes Obes Metab,2008,10(1):82-90.
[5]
Hassanein M,Hanif W,Malik W,et al.Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin,in Muslim patients with type 2 diabetes mellitus fasting during Ramadan:results of the VECTOR study[J].Curr Med Res Opin,2011,27:1367-1374.
[6]
Devendra D,Gohel B,Bravis V,et al.Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan[J].Int J Clin Pract,2009,63:1446-1450.
[7]
Al Sifri S,Basiounny IA,Echtay A,et al.The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan:a randomised trial[J].Int J Clin Pract,2011,65:1132-1140.
[8]
W Hanif,W Malik,M Hassanein,et al.Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan[J].Current Medical Research & Opinion,2013,29:807-811.
[9]
Arif Z.A guide to Ramadan[J].Nursing Standard,1992,18(26):45.
[10]
Aadil N,Houti IE,Moussamih S.Drug intake during Ramadan[J].BMJ,2004,329:778-782.
